Virtual Library
Start Your Search
Y.C. Ahn
Author of
-
+
P2.02 - Poster Session/ Treatment of Localized Disease – NSCLC (ID 210)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Localized Disease - NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.02-039 - Patterns-Of-Care Study of Stereotactic Ablative Radiotherapy for Lung Cancer in Korea (ID 164)
09:30 - 09:30 | Author(s): Y.C. Ahn
- Abstract
Background:
Stereotactic ablative radiotherapy (SABR) is an emerging effective technique for early stage lung cancer. We investigated the current practice patterns for stereotactic ablative radiotherapy (SABR) for lung cancer in Korea.
Methods:
A nationwide survey about experience with SABR for lung cancer was sent by e-mail to the radiation oncologists of 85 institutions in May 2014. SABR was defined as hypofractionated radiotherapy (1–8 fractions). The survey contained 23 questions, and those regarding technical details allowed multiple choices.
Results:
Of the 59 institutions that responded to the survey, 33 (56%) had used SABR for lung cancer. Thirty-seven radiation oncologists from these 33 institutions responded to the survey. Seventy-five percent of the oncologists had been treating lung cancer with SABR for less than 5 years, while 89% treat less than 20 cases annually. The most common planning method was rotational intensity-modulated technique (59%), followed by static intensity-modulated technique (49%). A wing board (54%) was most frequently used for immobilization, followed by the vacuum lock system (51%). Respiratory motion was managed by gating (54%) or abdominal compression (51%), and 86% of the planning scans were obtained with 4-dimensional computed tomography. More than half of the respondents (62%) treated daily if a multi-fraction regimen was used.
Conclusion:
The results of our survey indicated that SABR for lung cancer is being used increasingly in Korea, and that the majority of radiation oncologists using this therapy have limited experience in its use. There was wide variation among institutions with regard to the technical protocols, which indicates that standardization is necessary prior to the initiation of further nationwide multi-center, randomized studies.
-
+
P3.03 - Poster Session/ Treatment of Locoregional Disease – NSCLC (ID 214)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Locoregional Disease – NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.03-001 - Comparison of Adjuvant Therapy Modes Following Resection in Lung Cancer Patients with Clinically (-) but Pathologically (+) N2 Disease (ID 1298)
09:30 - 09:30 | Author(s): Y.C. Ahn
- Abstract
Background:
Mediastinal nodal staging is very important before recommending surgical resection in newly diagnosed non-small cell lung cancer patients. Following curative resection for having apparently clinically uninvolved mediastinal node (cN0-1), some proportion of patients, however, turns out to have pathologically involved mediastinal node (pN2). There have been controversies on optimal adjuvant therapy during past 2 decades in this clinical setting. Systemic chemotherapy, either followed by or concurrent with radiation therapy, has remained most important modality. This study is to evaluate clinical outcomes following similar, but different, 3 adjuvant therapy modalities, in all of which included systemic chemotherapy, at authors’ institute.
Methods:
Between 2006 and 2012, authors identified 240 cN0-1/pN2 patients who received adjuvant systemic chemotherapy following curative resection: chemotherapy alone in 85 patients (Group A); chemotherapy concurrent with thoracic radiation therapy (CCRT) in 68 (Group B); and CCRT followed by consolidation chemotherapy in 87 (Group C), respectively. Chemotherapy dose intensity was lower in CCRT setting than in upfront or consolidation chemotherapy settings, while thoracic radiation therapy dose schedule was the same (50 Gy/25 fractions). Clinical outcomes of loco-regional control (LRC), distant-metastasis free survival (DMFS) and overall survival (OS) were compared among Groups.
Results:
Median follow-up duration was 30 (5~93) months. Median age of all patients was 60 years and 149 patients (62.1%) were male. Majority of patients (224 patients, 93.3%) underwent lobectomy, while 16 (6.7%) did pneumonectomy. Adenocarcinoma was most common in 165 patients (68.8%) followed by squamous cell carcinoma in 53 (22.1%), and others in 22 (9.2%). There was no difference among Groups with respects to pretreatment and treatment characteristics except median age (Group A was older: 63 years vs. 58 years vs. 58 years, p=0.022). LRC, DMFS and OS rates at 5 years in all patients were 75.1%, 38.0% and 76.2%, respectively. Though no significant difference in OS at 5 years among Groups (76.8% vs. 68.4% vs. 82.5%, p=0.096), LRC rate at 5 years was significantly improved by addition of thoracic radiation therapy (62.9% vs. 78.9% vs. 82.9%, p=0.011), while DMFS rate at 5 years was significantly improved by delivering full dose chemotherapy (40.6% vs. 19.4% vs. 28.6%, p=0.018).
Conclusion:
Although in retrospective nature having potential selection bias, current observations support that maximal benefit could be achieved by thoracic radiation therapy concurrent with chemotherapy and consolidation full dose chemotherapy with respects to LRC and DMFS. Further prospective clinical trial would be desired.
